Cardiac Imaging

Echo Clues: When to Suspect Amyloidosis

cardiac amyloidosis echo

Aortic stenosis and cardiac amyloidosis cause similar functional and morphological changes in the heart, and discerning between the two conditions can be difficult. But in this European Heart Journal meta-analysis, researchers brought to light key differences in a large number of conventional echo criteria that can predict the presence of cardiac amyloidosis (CA) in aortic stenosis (AS) patients. 

The authors reviewed observational data from 1,449 patients (160 AS-CA and 1,289 AS-only) and found that the following features were significantly higher in patients with AS-CA compared with AS-only patients:

  • interventricular septal thickness (standardized mean difference: 0.74)
  • relative wall thickness (SMD: 0.74) 
  • posterior wall thickness (SMD: 0.74
  • LV mass index (SMD: 1.62)
  • E/A ratio (SMD: 4.18)
  • LA dimension (SMD: 0.73)

In contrast, these attributes were significantly lower in AS-CA patients:

  • myocardial contraction fraction (SMD: −2.88)
  • average mitral annular S′ (SMD: −1.14)
  • tricuspid annular plane systolic excursion (SMD: −0.36)
  • tricuspid annular S′ (SMD: −0.77)

The Takeaway

As the study’s editorial put it, the authors have revealed a “fundamental principle.” Routine echocardiographic parameters may prove to be “the key” to spotting cardiac amyloidosis in the presence of aortic stenosis. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!